Porama Thanaporn
Clinical Assistant Professor
Internal Medicine
Medicine
MD, University of Michigan
Dr. Thanaporn’s primary interests are in repurposing old drugs for new indications and the use of novel therapeutics in heart failure. He is also interested in heart failure outcomes and clinical trial design. He is currently co-PI for EMERALD-HF, a precision medicine heart failure trial in China using spironolactone in patients with aldehyde dehydrogenase type 2 deficiency, a common hereditary disorder that interferes with the metabolism of alcohol.
Projects:
EMERALD-HF: Evaluation of MinERalocorticoid antagonists in ALdehyde dehydrogenase type 2 Deficiency
University Affiliation(s)
Global REACH | IHPI | MiCHAMP
Research Area(s)
Clinical research | Global Health | cardiovascular diseases
Publications
- Erratum: P-selectin and leukocyte microparticles are associated with venous thrombogenesis (Journal of Vascular Surgery (2003) 38 (1075-1089))
- In vivo post-cardiac arrest myocardial dysfunction is supported by Ca2+/calmodulin-dependent protein kinase II-mediated calcium long-term potentiation and mitigated by alda-1, an agonist of aldehyde dehydrogenase type 2
- Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model